Up next

Autoplay

Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma

1 Views • 07/18/23
Share
Embed
administrator
administrator
Subscribers
0

William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay